XERS Stock Analysis: Buy, Sell, or Hold?
XERS - Xeris Biopharma Holdings, Inc. Common Stock
$8.19
0.05 (0.68%)
▲
5d:
-0.67%
30d:
-2.21%
90d:
+29.1%
BUY
HIGH Confidence
Analysis Updated: Aug 3, 2026 12:00 AM ET
Earnings: Aug 06, 2026
1d
Get Alerted When XERS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: XERS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: XERS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$14.52
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$9.02
9.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 19.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: XERS is currently trading at $8.19, which is considered slightly low relative to its 30-day fair value range of $7.96 to $8.67. The stock's valuation (Forward PE: 20.7) is in line with its historical norms (19.0). At these levels, the market is pricing in 2.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, XERS is in a strong uptrend. Immediate support is located at $7.87, while resistance sits at $8.76.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.29 (+38.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, XERS is in a strong uptrend. Immediate support is located at $7.87, while resistance sits at $8.76.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.29 (+38.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$7.96 -
$8.67
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
80.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 38.8% below Wall St target ($11.29)
- NEUTRAL: Market pricing in 2.8% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$7.96 -
$8.67
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$7.87
Resistance Level
$8.76
Current Trend
Strong Uptrend
Technical data as of
Aug 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
20.71
Wall Street Target
$11.29
(+38.8%)
Revenue Growth (YoY)
38.3%
Profit Margin
3.8%
Valuation Premium vs History
+2.8% premium
PE vs Historical
20.7 vs 19.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.8%
(market-implied from PE analysis)
1-Year Target
$8.36
(+3%)
2-Year Target
$8.59
(+6%)
3-Year Target
$8.83
(+9%)
3-Yr Target (if PE normalizes)
(PE: 21→19)
PE COMPRESSION
$8.10
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: 175.4%)
$27.46
(+238%)
Base:
(SPY PE: 20.7, Growth: 175.4%)
$27.44
(+238%)
Bear:
(PE: 17.6, Growth: 175.4%)
$23.32
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (101x PE), but valuation improves significantly next year (21x PE) as earnings recover.
Forward PE: 101.01 | Forward EPS (Implied): $0.08
Bull Case
$9.82
(+21%)
Analyst growth 15.0%, PE expands to 106.1
Base Case
$8.13
(0%)
Market implied 0.0%, PE stable at 101.0
Bear Case
$6.22
(-24%)
Severe decline -15.0%, PE contracts to 90.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 04, 2026 1:09 PM ET
Data refreshes hourly during market hours. Next update: 2:09 PM
Data refreshes hourly during market hours. Next update: 2:09 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XERS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Beth Hecht
SELL
16667 shares
2026-04-01
James Aloysius Brady
SELL
10834 shares
2026-03-30
Beth Hecht
SELL
16667 shares
2026-03-02
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 58 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$112 | 49 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$113 | 46 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$663 | 48 HOLD |